Greenwich LifeSciences’ FLAMINGO-01 Trial Confirms Strong Safety Profile

Greenwich LifeSciences has shared encouraging updates on its Phase III FLAMINGO-01 trial, which is evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The study’s independent Data Safety Monitoring Board (DSMB) met twice in 2024, including in December, and recommended continuing the trial without any changes. Most notably, no serious adverse events related to GLSI-100 have been reported. Early results align with findings from the previous Phase IIb study, where the therapy showed an 80% or greater reduction in recurrence rates for HER2/neu 3+ patients. The most common side effect has been mild injection site reactions, an expected sign of immune response activation.

CEO Snehal Patel expressed confidence in the therapy’s potential, emphasizing that these safety results reinforce GLSI-100’s promise as a well-tolerated immunotherapy for breast cancer patients. With patient enrollment progressing, researchers are eager to analyze immune response data further and compare it with earlier trials. If trends continue, these findings could be shared at upcoming scientific conferences, offering new hope for those seeking effective long-term cancer prevention.